NAMS

NewAmsterdam Pharma Co N.V.

Phase 3 AI-extracted

obicetrapib

cardiovascular disease

Countdown

177days

Phase 3 readout · ~ Dec 31, 2026 estimated

What's at stake Phase 3 trial results for obicetrapib in cardiovascular disease are due ~ Dec 31, 2026. A clean hit validates the program; a miss can gap the stock down hard.

Primary source · SEC 8-K verified 13h ago

“additional data from the Phase 3 BROADWAY, TANDEM, and BROOKLYN trials relating to obicetrapib and the FDC of obicetrapib plus ezetimibe”

Add to calendar Post on X Reddit

Provenance